Associate Professor of Medicine, Johns Hopkins University School of Medicine
Infectious Disease
Dr. Eric L. Nuermberger, MD
|
|
Give Review
Eric Nuermberger is an expert in the field of Infectious Disease. He researched medicine at Vanderbilt University School of Medicine. Eric L. Nuermberger is a published MD. He published 91 publications, including: 'Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum.'
Publications
- Shortening tuberculosis treatment with fluoroquinolones: lost in translation?
- Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum.
- Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis.
- Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
- Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
- Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
- A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.
- Correction for lanoix et Al., novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tubercu...
- Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
- Primary HIV infection presenting as limbic encephalitis and rhabdomyolysis.
- Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
- Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
- Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of multidrug-resistant tuberculosis cases.
- Principles for designing future regimens for multidrug-resistant tuberculosis.
- Pipeline of drugs for related diseases: tuberculosis.
- Potent rifamycin-sparing regimen cures Guinea pig tuberculosis as rapidly as the standard regimen.
- World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?
- Bactericidal Activity Does Not Predict Sterilizing Activity: The Case of Rifapentine in the Murine Model of Mycobacterium ulcerans Disease.
- Reply to "contradictory results with high-dosage rifamycin in mice and humans".
- Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
- Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
- Old Drugs, New Purpose: Retooling Existing Drugs for Optimized Treatment of Resistant Tuberculosis.
- Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium.
- Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
- Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
- Autoluminescent Mycobacterium tuberculosis for Rapid, Real-Time, Non-Invasive Assessment of Drug and Vaccine Efficacy.
- Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions.
- Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
- Short-course Chemotherapy with TMC-207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection.
- Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune-deficient Mice.
- Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.
- Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.
- PA-824 exhibits time-dependent activity in a murine model of tuberculosis.
- Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
- Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
- BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.
- Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
- The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models.
- Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
- Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment.
- Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
- Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.
- Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models.
- Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
- Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
- Evaluation of new antituberculosis drugs in mouse models.
- Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
- Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
- Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat.
- Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
- Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice.
- Antibiotic resistance in Streptococcus pneumoniae: what does the future hold?
- Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
- Polymerized human Hb use in acute chest syndrome: a case report.
- Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of Mycobacterium ulcerans Disease.
- Rapid, Serial, Non-invasive Assessment of Drug Efficacy in Mice with AutoluminescentMycobacterium ulcerans Infection.
- Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
- Cases from the Osler Medical Service at Johns Hopkins University. Diagnosis: Polymorphic population of mature and immature hematopoietic cells consistent with extramed...
- Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids.
- Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.
- Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG.
- The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative.
- Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes.
- Significance of macrolide resistance in Streptococcus pneumoniae.
- Latent tuberculosis infection.
- Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
- Murine models of pneumococcal pneumonia and their applicability to the study of tissue-directed antimicrobials.
- Low-dose aerosol model of pneumococcal pneumonia in the mouse: utility for evaluation of antimicrobial efficacy.
- Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
- In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
- Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
- Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).
- Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice.
- Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
- Older antibiotic gains new respect as potent treatment for tuberculosis. Rifapentine is already approved for use with humans.
- Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
- Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility.
- Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
- Using animal models to develop new treatments for tuberculosis.
- Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
- Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
- Tuberculosis in transplant recipients: diagnostic and therapeutic dilemmas.
- Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
- Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
- Comparison of the ''Denver regimen'' against acute tuberculosis in the mouse and guinea pig.
- Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.
- The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters.
- Current development and future prospects in chemotherapy of tuberculosis.
- Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
- Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
Schools
Vanderbilt University
Johns Hopkins Hospital
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
Johns Hopkins University -
Vanderbilt University School of Medicine
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1477593150 |
| Last Name Of The Provider | NUERMBERGER |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
|
Dr. Christie Basseth, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shelley S. Magill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kent E. Kester, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Oluwaseun O. Falade-Nwulia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce L. Gilliam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mona K. Gahunia, DO |
|
|
Dr. Anne M. Rompalo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Said, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas C. Macharia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Damani A. Piggott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann S. Vorys, MD
This Doctor is OpenDoctor Recommended.
|